Comorbid asthma, nonsmoking status, and the ethmoid/maxillary sinus ratio were significant predictors of eosinophilic CRSwNP.

For the first time in half a century, scientists have hit on a new treatment for asthma attacks. Clinical trial results have ...

Discover how benralizumab offers superior outcomes for eosinophilic asthma and COPD exacerbations, outperforming steroids in ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD ...

Apogee plans to take a combination approach to AD by targeting Types 1-3 inflammation potentially offering JAK-like inhibition without their ...

Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dos ...

A drug already used in the treatment of severe asthma could help treat exacerbations in asthma and COPD, a UK trial has found ...

An injection of a drug already on the market, Benralizamab, promises to be the next revolution in the treatment of asthma ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease ...

The first new treatment for asthma attacks in 50 years is a drug already available—and it’s 4x more effective than steroid ...

Treatment for asthma and chronic obstructive pulmonary disease (COPD), which contributed to Sinead O'Connor's death last year ...

Study, published in The Lancet Respiratory Medicine, has revealed that a drug called benralizumab - administered as an ...